Literature DB >> 20417866

Acute myeloid leukemia (AML-M2) associated with variant t(8;21): report of three cases.

Sook Young Bae1, Jang Su Kim, Bung Jun Ryeu, Kap No Lee, Chang Kyu Lee, Young Kee Kim, Chae Seung Lim, Yunjung Cho, Chul Won Choi, Sook-Won Ryu, Soo-Young Yoon.   

Abstract

Variants of the t(8;21)(q22;q22) involving chromosome 8, 21, and other chromosomes account for approximately 3% of all t(8;21)(q22;q22) found in patients with acute myeloid leukemia (AML). The clinicopathologic features of AML with the variant t(8;21) have not been well established. We report three cases of AML with variants of t(8;21) characterized, respectively, by derivative 8 with the interstitial inverted insertion of 21q and concurrent monosomy 21, t(8;18;21)(p22;q11.3;q22), and t(2;21;8)(q11.2;q22;q22). Fluorescence in situ hybridization or reverse transcriptase-polymerase chain reaction assay confirmed the presence of RUNX1-RUNX1T1 gene (previously AML1-ETO) rearrangements. Among these cases, three-way breakpoints 18p11.3 and 2q11.2 have not been previously reported. The present report deals with the results of hematologic, immunophenotypic, cytogenetic, fluorescence in situ hybridization, and molecular analyses of these variants. The possible role of the genes in this region in leukemogenesis, response to treatment, and clinical implications are discussed. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20417866     DOI: 10.1016/j.cancergencyto.2009.10.002

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  2 in total

Review 1.  Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia.

Authors:  Yahya Daneshbod; Leila Kohan; Vahideh Taghadosi; Olga K Weinberg; Daniel A Arber
Journal:  Curr Treat Options Oncol       Date:  2019-02-11

2.  Clinical, Cytogenetic, and Molecular Findings in Two Cases of Variant t(8;21) Acute Myeloid Leukemia (AML).

Authors:  Lindsay Wilde; Jillian Cooper; Zi-Xuan Wang; Jinglan Liu
Journal:  Front Oncol       Date:  2019-10-04       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.